Picard Medical, Inc. (PMI) Stock Price & Analysis
Picard Medical, Inc. (PMI) — MoonshotScore 23/100 (Weak band), calculated Nov 18, 2026. Price $6.79 (+7.78%), as of the Nov 20, 2026 trading session; market cap $18.1M.
Educational signal · not a buy or sell recommendation · How to read this
Picard Medical, Inc. · PMI
Picard Medical, Inc. (PMI) specializes in the commercialization of medical devices, notably the SynCardia TAH, a total artificial heart.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Picard Medical (PMI)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Bottom-tier quality and an expensive valuation, though growth is only middling. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Okay; Valuation: Bubble; Growth Durability: Flat; Momentum: Quiet.
- quarterly revenue $1M (Q3 FY2025, quarter ended Sep 2025)
- Altman Z 37.76 · Piotroski F 3
Holding back: weak fundamentals, a rich price
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 25 | Weak | |
| 25 | Weak | |
| 25 | Weak | |
| 23 | Weak | |
| 23 | Weak | |
| 23 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $6.79 | |
| Change on the day | +7.78% | |
| Market capitalisation | $18.1M | — |
| Shares traded on the day | 20.3K |
Price & events
Other perspectives
Council score for Picard Medical (PMI): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 20, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
One of these lenses reads this company more favourably than the MoonshotScore does: Dalio-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Picard Medical (PMI), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Picard Medical, Inc. (PMI) is the company analyzed here. It employs 75 people. In Q3 FY2025 it reported revenue of $1M and net income of -$10M. The market values it at $18.1M.
What do the latest results show for Picard Medical (PMI)?
Short answer · as of
The most recent reported quarter, Q3 FY2025, carried revenue of $1M.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2025 | $1M | -$10M | -$9.57 (diluted) |
| Q4 FY2025 | $1M | -$4M | — |
| Q1 FY2026 | $1M | -$8M | -$5.12 (diluted) |
| Q2 FY2026 | $3M | -$6M | -$3.05 (diluted) |
What are the financial strengths and risks for Picard Medical (PMI)?
Short answer
What is holding it back is weak fundamentals, a rich price. The distress and quality screens read Altman Z 37.76 · Piotroski F 3. Trailing ratios: ROA -78.8% · current ratio 0.99.
How does Picard Medical compare with its peers?
Short answer
Picard Medical's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $22.98 Nov 20, 2026 | $188M | 87 5-pillar Nov 18, 2026 | |
| $99.94 Nov 20, 2026 | $128B | 81 5-pillar Nov 18, 2026 | |
| $313.08 Nov 19, 2026 | $119B | 80 5-pillar Nov 18, 2026 | |
| $41.98 Nov 20, 2026 | $60.9B | 77 5-pillar Nov 18, 2026 | |
| $13.23 Nov 20, 2026 | $177M | 71 5-pillar Nov 18, 2026 | |
| $103.00 Nov 20, 2026 | $178B | 69 5-pillar Nov 18, 2026 | |
| $4.64 Nov 19, 2026 | $57.1M | 44 5-pillar Nov 18, 2026 | |
| $1.49 Nov 20, 2026 | $93.7M | 43 5-pillar Nov 18, 2026 | |
| $3.23 Nov 19, 2026 | $96.5M | 41 5-pillar Nov 18, 2026 | |
| $2.08 Nov 20, 2026 | $31.7M | 39 5-pillar Nov 18, 2026 | |
| $5.30 Nov 20, 2026 | $138M | 37 5-pillar Nov 18, 2026 | |
| $6.07 Nov 20, 2026 | $247M | 36 5-pillar Nov 18, 2026 | |
| Picard Medical (PMI) — this page | $6.79 | $18.1M | 23 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Insider activity
Form 4 records via FMP · Most recent available transactions
- Transactions
- 12
- Identified insiders
- 3
- Purchases
- 0
- Sales
- 0
- Other transactions
- 12
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held PMI in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported PMI in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Picard Medical (PMI)?
Investor Questions: PMI Stock
These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.
What does the MoonshotScore mean for PMI?
PMI carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is PMI a good stock to buy?
Stock Expert AI does not rate PMI buy, sell or hold. Picard Medical, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the PMI stock price today?
The last price recorded for Picard Medical, Inc. (PMI), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the key factors to evaluate for PMI?
Picard Medical, Inc. (PMI) holds a MoonshotScore in the low range. Collaborations can lead to increased market access and shared resources, driving growth and innovation over the next few years. Not financial advice.
How frequently does PMI data refresh on this page?
PMI's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven PMI's recent stock price performance?
Picard Medical, Inc. (PMI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative product offerings, particularly the SynCardia TAH. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PMI overvalued or undervalued right now?
Picard Medical, Inc. (PMI) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research PMI before investing?
Before investing in Picard Medical, Inc. (PMI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding PMI to a portfolio?
Key strength of Picard Medical, Inc. (PMI): Innovative product offerings, particularly the SynCardia TAH. Weigh rewards against risks and diversify. Not financial advice.
Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 13 figures on this page — 9 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com